FASN and cancer: Most efforts to pharmacologically inhibit lipid synthesis have focussed on FASN, and the effects of inhibitors of this enzyme have been investigated in different preclinical cancer models (Kuhajda et al., 2000; Li et al., 2001; Puig et al., 2009; Zhan et al., 2008).